Assessment of ofloxacin for community-acquired LRTIs

Infections in Medicine

Volumn 13, Issue 2, 1996, Pages 141-151

  Kahn, James B ^a  

^a Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

chlamydia; erythromycin; fluoroquinolones; infections, respiratory tract; penicillin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFACLOR; CEFAZOLIN; CEFIXIME; CEFOTAXIME; CEFPIMIZOLE; CEFTAZIDIME; CEFTAZIDIME ARGININE; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; LINCOMYCIN; LOMEFLOXACIN; NORFLOXACIN; OFLOXACIN; OLEANDOMYCIN; PENICILLIN G; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; DRUG TISSUE LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEGIONELLA PNEUMOPHILA; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA PNEUMONIAE; REVIEW;

EID: 0029986798     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Macfarlane JT, Colville A, Guion A, et al: Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet 341:511-515, 1993.
2. Ortqvist A: Community-acquired lower respiratory infection. Lancet 341:529-530, 1993.
3. Forsberg P, Maller R, Nilsson L: Comparative study of oral ofloxacin and erythromycin in the treatment of pneumonia. Rev Infect Dis 11 (suppl 5):S1229-S1230, 1989.
4. Carlson NC, Kuskie MR, Dobyns EL, et al: Legionellosis in children: An expanding spectrum. Pediatr Infect Dis J 9:133-137, 1990.
5. Grayston JT, Diwan VK, Cooney M, et al: Community- and hospital-acquired pneumonia associated with Chlamydia TWAR infection demonstrated serologically. Arch Intern Med 149:169-173, 1989.
6. Mycoplasma pneumoniae (editorial). Lancet 337:651-652, 1991.
7. Marston B, Plouffe J, Breiman R, et al: Preliminary findings of community-based pneumonia incidence study (CBPIS). Proceedings of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract 55, Chicago, 1991.
8. Cummings MC, McCormack GM: Mycoplasmas and Ureaplasmas, in Gorbach SL, Bartlett JG, Blacklow NR (eds): Infectious Diseases. W. B. Saunders, Philadelphia, 1992, pp1641-1645.
9. Outbreaks of Mycoplasma pneumoniae respiratory infections - Ohio, Texas, and New York, 1993. MMWR 42:931-939, 1993.
10. Sillis M: Mycoplasma pneumoniae. Lancet 337:1101, 1991.
11. Alshafi KM, Ironton R: Unusual presentation of Mycoplasma pneumoniae infection. Lancet 338:1519-1520, 1991.
12. Cassell GH, Waites KB, Pate MS, et al: Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin and lomefloxacin. Rev Infect Dis 11 (suppl 5):S992, 1989.
13. Grayston JT, Kuo C-C, Wang S-P, et al: A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 315:161-168, 1986.
14. Grayston JT, Mordhorst C, Bruu A, et al: Countrywide epidemics of Chlamydia pneumoniae, strain TWAR, in Scandinavia, 1961-1983. J Infect Dis 159:1111-1114, 1989.
15. Hammerschlag MR, Chirgwin K, Roblin PM, et al: Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis 14:178-82, 1992.
16. Saikku P, Leinonen M, Tenkanen L, et al: Chronic Chlamydia pneumonias infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Annals Intern Med 116:273-278, 1992.
17. Lipsky BA, Tack KJ, Kuo CC, et al: Ofloxacin treatment of Chlamydia pneumonias (strain TWAR) lower respiratory tract infections. Am J Med 89:722-724, 1990.
18. Dark DS, Farber M, Rice K, et al: Oral ofloxacin versus cefaclor for LRTIs in adults. Infect Med 12(10):551-556, 1995.
19. Chirgwin K, Robin PM, Gelling M, et al: Infection with Chlamydia pneumoniae in Brooklyn. J Infect Dis 163:757-761, 1991.
20. Hammerschlag MR, Chirgwin K, Robin PM, et al: Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis 14:178-182, 1992.
21. Harrison TG, Saunders NA, Haththotuwa A, et al: Phenotypic variation amongst genotypical homogeneous Legionella pneumophila serogroup 1 isolates: Implications for the investigation of outbreaks of legionnaires' disease. Epidemiol Infect 104:171-180, 1990.
22. Mandell GL, Douglas RG, Bennett JE, eds: Principles and practice of infectious diseases, ed 3. New York, Churchill Livingstone, 1990.
23. Plouffe J, Herbert M, File T, et al: Clinical and economic assessment of ofloxacin vs standard therapy for community-acquired pneumonia requiring hospitalization. Abstract A-123, 95th Am Soc Microbiol General Meeting, 1995, Washington, DC.
24. Luby JP: Pneumonia caused by Mycoplasma pneumoniae infection. Clin Chest Med 12:237-243, 1991.
25. Martin RE, Bates JH: Atypical pneumonia. Infect Dis Clin North Am 5:585-601, 1991.
26. Wilson JD, Braunwald E, Isselbacher KJ, et al (eds): Harrison's Principles of Internal Medicine, ed 12. New York, McGraw-Hill, 1991.
27. Grayston JT, Campbell LA, Kuo CC, et al: A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 161:618-625, 1990.
28. Niederman MS, Bass JB Jr, Campbell GD, et al: Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity and initial antimicrobial therapy. Am Rev Respir Dis 148:1418-1426, 1993.
29. Cherubin CE, Eng RHK, Smith SM, et al: A comparison of antimicrobial activity of ofloxacin, L-ofloxacin, and other oral agents for respiratory pathogens. Diagn Microbiol Infect Dis 15:141-144, 1992.
30. Saito A, Koga H, Shigeno H, et al: The antimicrobial activity of ciprofloxacin against Legionella species and the treatment of experimental Legionella pneumonia in guinea pigs. J Antimicrob Chemother 18:251-260, 1986.
31. Hansman D, Bullen MM: A resistant pneumococcus [letter]. Lancet 2:264-265, 1967.
32. Appelbaum PC, Bhamjee A, Scragg JN, et al: Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 2:995-997, 1977.
33. Appelbaum PC: Antimicrobial resistance in Streptococcus pneumoniae; an overview. Clin Infect Dis 15:77-83, 1992.
34. Breiman RF, Butler JC, Tenover FC, et al: Emergence of drug-resistant pneumococcal infections in the United States. JAMA 271:1831-1835, 1994.
35. Jones RN, Erwin ME, Anderson SC, et al: The continuing role of fluoroquinolone antimicrobial agents: Report of a 43-hospital surveillance study (Abstract). Fifth International Symposium on New Quinolones. Singapore, August 25-27, 1991.
36. Jorgensen JH, Doern GV, Maher LA, et al: Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 34:2075-2080, 1990.
37. Centers for Disease Control: Drug-resistant Streptococcus pneumoniae - Kentucky and Tennessee, 1993. MMWR 43:23-25, 1994.
38. Lonks JR, Medeiros AA: High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I. Antimicrob Agents Chemother 37:1742-1745, 1993.
39. Brown SD, Thornsberry C, Marler JK, et al: Activity of ofloxacin and other antibiotics against penicillin-resistant, penicillin-relatively resistant, and penicillin-susceptible S. pneumoniae. A-39,93rd American Society of Microbiology General Meeting, Atlanta, 1993. Abstract.
40. O'Brien TF. Global surveillance of antibiotic resistance. N Engl J Med 326:339-340, 1992.
41. Seppala H, Nissinen A, Jarvinen H, et al: Resistance to erythromycin in group A streptococci. N Eng J Med 326:292-297, 1992.
42. Nitu Y, Hasegawa S, Suetake T, et al: Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics. J Pediatrics 76:438-443, 1970.
43. Shames JM, George RB, Holliday WB, et al: Comparison of antibiotics in the treatment of mycoplasmal pneumonia. Arch Intern Med 125:680-684, 1970.
44. Slotkin RI, Clyde WA, Denny FAV: The effect of antibiotics on Mycoplasma pneumoniae in vitro and in vivo. Am J Epidemiol 86:225-237, 1967.
45. The choice of antimicrobial drugs. The Medical Letter on Drugs and Therapeutics 34:49-56, 1992.
46. Chodosh S: Use of quinolones for the treatment of chronic bronchitis. Am J Med 91(suppl 6A]:93S-100S, 1991.
47. Lee BL, Kimbrough RC, Jones SR, et al: Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 325:520-521, 1990.
48. Frieden TR, Mangi RJ: Inappropriate use of ciprofloxacin. JAMA 264:1438-1440, 1990.
49. Pedersen SS, Jensen T, Hvidberg EF: Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. J Antimicrob Chemother 20:575-583, 1987.
50. Stratton CW: Comparison of killing kinetics for selected fluoroquinolones vs selected cell-wall-active agents against Streptococcus pneumoniae (Abstract). Fifth International Symposium on New Quinolones. Singapore, August 25-27, 1994.
51. Amyes SGB, Baird DR, Crook DW, et al: A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin, and ciprofloxacin against blood and urinary pathogens. J Antimicrob Chemother 34:639-648, 1994.
52. Courand L, Gourtillan JB, Saux MC, et al: Diffusion of ofloxacin into human lung tissue. Drugs 34(suppl 1):37-38,1987.
53. Koga H: High-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes. Antimicrob Agents Chemother 31:1904-1908, 1987.
54. Lode H, Hoffken G, Olschewski P, et al: Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother 31:1338-1342, 1987.
55. Todd PA, Faulds D: Ofloxacin: A reappraisal of its antimicrobial activity, pharmacology and therapeutic use. Drugs 42:825-876, 1991.
56. Wolfson JS, Hooper DC: Comparative pharmacokinetics of ofloxacin and ciprofloxacin. Am J Med 87(suppl 6C):31S-36S, 1989.
57. Gentry LO, Rodriguez-Gomez G, Kohler RB, et al: Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization. Am Rev Respir Dis 145:31-35, 1992.
58. Sanders WE Jr, Morris JF, Alessi P, et al: Oral ofloxacin for the treatment of acute bacterial pneumoniae: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial. Am J Med 91:261-266, 1991.
59. Gentry LO, Lipsky B, Farber MO, et al: Oral ofloxacin therapy for lower respiratory tract infections. South Med J 85:14-18, 1992.
60. Leroy O, Beuscart C, Chidiac C, et al: Therapy of pneumonias due to Legionella, Mycoplasma, Chlamydia, and Rickettsia with ofloxacin. Path Biol 37:1137-1140, 1989.
61. Stocks JM, Wallace RJ Jr, Griffith DE, et al: Ofloxacin in community-acquired lower respiratory infections: A comparison with amoxicillin or erythromycin. Am J Med 87(suppl C):52C-56C, 1989.
62. Wynckel A, Toupance O, Melin JP, et al: Treatment of legionellosis with ofloxacin in kidney transplanted patients: Lack of interaction with cyclosporine A. Presse Med 20:291-293, 1991.
63. Mouton Y, Leroy O, Beuscart C, et al: Efficacy of intravenous ofloxacin: A French multicenter trial in 185 patients. J Antimicrob Chemother 26(suppl D):115-121, 1990.
64. The Ovation Report on Cost Effective Products: Economic impact of a quinolone antibiotic in the treatment of pneumonia. Ovation Healthcare Research, Inc. Highland Park, Ill., 1992.
65. Oriel JD: Use of quinolones in chlamydial infection. Rev Infect Dis 11(suppl 5):S1273-S1276, 1989.
66. Hammerschlag MR, Hyman CL, Roblin PM: In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob Agents Chemother 36:682-683, 1992.
67. Barry AL: In vitro activity of the fluoroquinolone compounds. Antimicrob Newsletter. 5:69-76, 1988.
68. Wadworth AN, Goa KL: Lomefloxacin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 42:1018-1060, 1991.
69. Campoli-Richards DM, Monk JP, Price A, et al: Ciprofloxacin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 35:373-447, 1988.
70. Warlich R, Korting HC, Schafer-Korting M, et al: Multiple-dose pharmacokinetics of ofloxacin in serum, saliva, and skin blister fluid of healthy volunteers. Antimicrob Agents Chemother 34:78-81, 1990.
71. Alestig K: The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin). Scand J Infect Dis 68(suppl):19-22, 1990.
72. Wijnands WJA, Vree TB, Baars AM, et al: The penetration of ofloxacin into lung tissue. J Antimicrob Chemother 22(suppl C):85-89, 1988.
73. Tallarigo C, Comunale L, Baldassare R, et al: Ofloxacin (Oflocin) : Evaluation of distribution in the prostate, clinical efficacy in bacterial prostatitis. Clin Trials J 26:233-237, 1989.